Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Viking Therapeutics (VKTX) shares plummeted over 41% after Phase 2 data for its oral obesity drug VK2735, despite showing up to 12.2% weight reduction, revealed higher discontinuation rates due to tolerability concerns, disappointing investors. William Blair, however, maintained an Outperform rating, deeming the sell-off excessive, citing the 30mg dose's placebo-like safety profile and potential for improved tolerability with extended titration, while emphasizing Viking's M&A appeal. This bullish outlook is tempered by competitive concerns regarding VK2735's efficacy relative to leading injectable GLP-1s and its high active pharmaceutical ingredient requirements.

Analysis

Viking Therapeutics (VKTX) experienced a significant 41.04% decline in its stock price following the release of its Phase 2 trial data for the oral obesity pill VK2735, despite the drug demonstrating promising efficacy. The data showed a mean body weight reduction of up to 12.2% from baseline after 13 weeks, a notable improvement from the 5.3% reduction observed in Phase 1. However, investor sentiment turned sharply negative due to a tolerability profile and discontinuation rates that were perceived as worse than in the initial study. In a contrarian view, William Blair labeled the market's reaction as "extreme and unwarranted," maintaining an Outperform rating. The firm's analyst highlighted that the 30 mg dose, a probable maintenance level, exhibited a placebo-like safety profile and suggested that extending the titration period in future studies could improve overall tolerability. William Blair also underscored Viking's potential as a favorable M&A target for large pharmaceutical companies. This bullish outlook is contested by concerns over the drug's competitive positioning and commercial viability. An independent analysis pointed out that VK2735's efficacy appears inferior to Eli Lilly's subcutaneous tirzepatide at a similar timeframe and, critically, requires 14 to 28 times more active pharmaceutical ingredient (API), posing a significant manufacturing cost headwind.

Key Decisions for Investors

• Investors with a high risk tolerance might view the 41% stock price drop as an overreaction and a potential entry point, aligning with the William Blair thesis that tolerability can be managed and the company remains a strong M&A candidate.
• Cautious investors should carefully consider the significant headwinds, including the drug's inferior efficacy profile compared to market leader Eli Lilly's tirzepatide and the substantial manufacturing cost challenges posed by the high API requirement.
• All parties should monitor for upcoming catalysts, specifically any announcements regarding pivotal trial design that include an extended titration period to address tolerability and company commentary on strategies to mitigate the high API cost for commercial viability.